Advanced glycosylation end products (AGEs), insulin-like growth factor-1 (IGF-1) and IGF-binding protein-3 (IGFBP-3) in patients with Type 2 diabetes mellitus

Background Advanced glycosylation end product (AGE) formation is a major mechanism for the development of complications in diabetes, and the possible roles of insulin‐like growth factor 1 (IGF‐1) and IGF binding protein 3 (IGFBP‐3) are not clearly established. Methods We examined the associations of...

Full description

Saved in:
Bibliographic Details
Published in:Diabetes/metabolism research and reviews 2000-03, Vol.16 (2), p.106-113
Main Authors: Garay-Sevilla, Ma. Eugenia, Nava, Laura Eugenia, Malacara, Juan Manuel, Wróbel, Kazimierz, Wróbel, Katarzyna, Pérez, Ulises
Format: Article
Language:English
Subjects:
advanced glycosylation end products
Biological and medical sciences
Biomarkers - blood
Blood Glucose - metabolism
Blood Pressure
Cholesterol - blood
Communicable Diseases - blood
complications of diabetes
Cross-Sectional Studies
diabetes mellitus
Diabetes Mellitus, Type 2 - blood
Diabetes Mellitus, Type 2 - complications
Diabetes. Impaired glucose tolerance
Diabetic Nephropathies - blood
diabetic nephropathy
Endocrine pancreas. Apud cells (diseases)
Endocrinopathies
Etiopathogenesis. Screening. Investigations. Target tissue resistance
Female
free IGF-1
Glycated Hemoglobin - analysis
Glycation End Products, Advanced - blood
Humans
IGFBP-3
Inpatients
Insulin-Like Growth Factor Binding Protein 3 - blood
Insulin-Like Growth Factor I - analysis
Insulin-Like Growth Factor I - metabolism
Kidney Failure, Chronic - blood
Male
Medical sciences
Middle Aged
Reference Values
Regression Analysis
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Advanced glycosylation end product (AGE) formation is a major mechanism for the development of complications in diabetes, and the possible roles of insulin‐like growth factor 1 (IGF‐1) and IGF binding protein 3 (IGFBP‐3) are not clearly established. Methods We examined the associations of AGEs, free IGF‐I and IGFBP‐3 in Type 2 diabetes mellitus (DM) patients under diverse conditions. In a cross‐sectional design we studied 110 subjects (67 women and 43 men): non‐diabetic controls in group 1, (n=15) and diabetes patients as follows: group 2, without complications (n=25); group 3, with chronic complications (n=25); group 4, with acute or chronic infections (n=24); group 5, hospitalized for reasons unrelated to diabetes (n=9); group 6, with end‐stage renal disease (ESRD) (n=12). AGEs were determined by a spectrofluorometric method (HPLC). Insulin and IGFBP‐3 were measured by RIA and free IGF‐1 with an IRMA method. Results AGEs were 13‐fold higher in patients with ESRD (p
ISSN:1520-7552
1520-7560
DOI:10.1002/(SICI)1520-7560(200003/04)16:2<106::AID-DMRR88>3.0.CO;2-H